GlassScriptPhysician profile
Elizabeth C Walters
NPI 1366925158
$8,136.47
in general payments reported to CMS, 2019-2025
31 companies · $2,451 in 2025
The $2,451 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $585 · 2022: $1,678 · 2023: $1,437 · 2024: $1,985 · 2025: $2,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,873.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,425.93 | 2021-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,219.69 | 2021-2025 | |
| Janssen Biotech, INC. | $774.04 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $602.33 | 2021-2025 | Entyvio |
| Genzyme Corporation | $434.39 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $418.96 | 2022-2025 | Dupixent |
| Pfizer INC. | $416.32 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $269.02 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $236.43 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $223.04 | 2021-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $212.59 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $206.15 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $203.00 | 2021-2025 | Ocaliva |
| Lilly USA, LLC | $195.66 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $173.60 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $139.52 | 2022-2025 | Givlaari |
| Celgene Corporation | $133.37 | 2022-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $117.55 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $114.93 | 2022-2023 | Clenpiq, Rebyota |
| Ironwood Pharmaceuticals, INC | $110.97 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $90.68 | 2022-2024 | Dificid |
| Braintree Laboratories, INC. | $68.24 | 2021-2024 | Sutab, Suflave |
| Amgen INC. | $61.47 | 2022-2023 | Amjevita |
| Novo Nordisk INC | $60.98 | 2025 | Wegovy |
| Celltrion USA INC. | $51.64 | 2024-2025 | Vegzelma |
| Shield Therapeutics INC | $51.13 | 2023-2024 | Accrufer |
| Redhill Biopharma INC. | $41.95 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.43 | 2023 | Zeposia |
| Hologic Sales and Service, LLC | $21.44 | 2023 | Fluent Fluid Management System |
| Fresenius Kabi USA, LLC | $17.42 | 2024 | Idacio |
| Sandoz INC. | $16.60 | 2025 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Walters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.